This trial will study whether it is better to stop treatment with PD-1/PD-L1 therapy after one year or continue until disease progression.
4 Primary · 3 Secondary · Reporting Duration: Between 4 months and 7.9 months
Active Control
Experimental Treatment
578 Total Participants · 2 Treatment Groups
Primary Treatment: Discontinue PD-1/PD-L1-1 inhibitor · No Placebo Group · Phase 3
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: